ViewsML has secured $4.9 million in new funding to advance its innovative platform for virtualizing immunohistochemistry (IHC). This investment round underscores confidence in the company's approach to transforming pathology analysis and accelerating biomarker discovery.
The company is developing the world's first virtual biomarker library, leveraging artificial intelligence to generate per-cell spatial insights directly from routine pathology images. This eliminates the need for physical IHC, a diagnostic process that has remained largely unchanged for decades. By virtualizing IHC, ViewsML enables scientists and clinicians to obtain biomarker staining results in minutes, a significant improvement over the days to weeks typically required by conventional methods. Its platform analyzes standard H&E pathology slides to predict biomarker spatial expression at the individual cell level, preserving precious tissue samples and integrating seamlessly into existing workflows.
This capital infusion is significant for ViewsML as it aims to accelerate the development and commercialization of its technology. The funds will be strategically deployed to expand the company's research and development capabilities, scale its operational infrastructure, and grow its team of AI and pathology experts. The goal is to further enhance the platform's capabilities, enabling faster biomarker discovery, accelerating clinical trials, and providing earlier insights to guide treatment decisions for patients.
ViewsML currently collaborates with leading pharmaceutical companies, diagnostic labs, and healthcare systems. The company is focused on unlocking the full biological value of existing pathology data. This new funding positions ViewsML to further its mission of enabling a faster, more scalable path to precision medicine, ultimately benefiting patient care globally.
